Activin and Inhibin

Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.Appearance:SolidIn Vivo:Frakefamide (LEF576) yields

Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.In Vivo:Frakefamide (LEF576) yields a dose dependent

Freselestat quarterhydrate (ONO-6818 quarterhydrate) is a potent and orally active neutrophil elastase inhibitor with a K i of 12.2 nM. Freselestat quarterhydrate is &gt:100-fold less-active against other proteases such as trypsin, protein-ase 3,

FSCPX is a potent and selective irreversible antagonist of A 1 adenosine receptor (A 1 AR) , with low nanomolar potency for binding to the A 1 AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial

FSCPX is a potent and selective irreversible antagonist of A 1 adenosine receptor (A 1 AR) , with low nanomolar potency for binding to the A 1 AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial

FSCPX is a potent and selective irreversible antagonist of A 1 adenosine receptor (A 1 AR) , with low nanomolar potency for binding to the A 1 AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial

FSHR agonist 1 is a high affinity and allosteric follicle stimulating hormone receptor (FSHR) agonist with a pEC 50 of 7.72. FSHR agonist 1 formes extensive interactions with the TMD to directly activate FSHRIn VitroThe binding of FSHR agonist 1

FSHR agonist 1 is a high affinity and allosteric follicle stimulating hormone receptor (FSHR) agonist with a pEC 50 of 7.72. FSHR agonist 1 formes extensive interactions with the TMD to directly activate FSHRIn VitroThe binding of FSHR agonist 1

FSHR agonist 1 is a high affinity and allosteric follicle stimulating hormone receptor (FSHR) agonist with a pEC 50 of 7.72. FSHR agonist 1 formes extensive interactions with the TMD to directly activate FSHRIn VitroThe binding of FSHR agonist 1

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.In VitroFT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.In VitroFT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.In VitroFT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits